Help me prepare for neet pg and inicet exams by making rapido revision notes for surgery that should be from standard textbook only on the topic breast which should be like taught by a excellent mbbs professor which should have pyqs and pyts images diagrams flowcharts and mnemonics.make it as aesthetic style
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
mkdir -p /home/daytona/workspace/breast-surgery-notes
Writing File
~/breast-surgery-notes/breast_surgery_neetpg.html
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>🩺 BREAST SURGERY — NEET PG / INICET Rapid Revision Notes</title>
<style>
:root {
--pink: #e91e63;
--pink-light: #fce4ec;
--pink-mid: #f48fb1;
--purple: #7b1fa2;
--purple-light: #f3e5f5;
--blue: #1565c0;
--blue-light: #e3f2fd;
--teal: #00695c;
--teal-light: #e0f2f1;
--orange: #e65100;
--orange-light: #fff3e0;
--red: #b71c1c;
--red-light: #ffebee;
--green: #1b5e20;
--green-light: #e8f5e9;
--yellow: #f9a825;
--yellow-light: #fffde7;
--bg: #fafafa;
--card-shadow: 0 4px 20px rgba(0,0,0,0.08);
--border-radius: 16px;
}
* { box-sizing: border-box; margin: 0; padding: 0; }
body {
font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
background: linear-gradient(135deg, #fce4ec 0%, #f3e5f5 30%, #e3f2fd 60%, #e0f2f1 100%);
min-height: 100vh;
padding: 20px;
color: #212121;
font-size: 15px;
line-height: 1.65;
}
/* ====== HEADER ====== */
.main-header {
text-align: center;
background: linear-gradient(135deg, #880e4f, #4a148c, #0d47a1);
color: white;
padding: 40px 30px;
border-radius: 24px;
margin-bottom: 30px;
box-shadow: 0 8px 32px rgba(136,14,79,0.35);
position: relative;
overflow: hidden;
}
.main-header::before {
content: '';
position: absolute;
top: -50%; left: -50%;
width: 200%; height: 200%;
background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.07) 0%, transparent 50%),
radial-gradient(circle at 70% 50%, rgba(255,255,255,0.05) 0%, transparent 50%);
}
.main-header h1 { font-size: 2.2em; font-weight: 800; letter-spacing: 1px; text-shadow: 0 2px 8px rgba(0,0,0,0.3); }
.main-header .subtitle { font-size: 1.05em; opacity: 0.9; margin-top: 8px; }
.badges { display: flex; justify-content: center; gap: 12px; flex-wrap: wrap; margin-top: 16px; }
.badge { background: rgba(255,255,255,0.2); padding: 6px 18px; border-radius: 20px; font-size: 0.85em; font-weight: 600; backdrop-filter: blur(4px); border: 1px solid rgba(255,255,255,0.3); }
/* ====== NAV PILLS ====== */
.toc {
background: white;
border-radius: var(--border-radius);
padding: 20px 25px;
margin-bottom: 28px;
box-shadow: var(--card-shadow);
border-left: 5px solid var(--pink);
}
.toc h3 { color: var(--pink); font-size: 1em; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 12px; }
.toc-grid { display: flex; flex-wrap: wrap; gap: 8px; }
.toc-item { background: var(--pink-light); color: var(--red); padding: 5px 14px; border-radius: 20px; font-size: 0.82em; font-weight: 600; cursor: pointer; transition: all 0.2s; text-decoration: none; border: 1.5px solid var(--pink-mid); }
.toc-item:hover { background: var(--pink); color: white; transform: translateY(-2px); }
/* ====== SECTION WRAPPER ====== */
.section { margin-bottom: 35px; }
.section-header {
display: flex; align-items: center; gap: 14px;
padding: 18px 24px;
border-radius: var(--border-radius) var(--border-radius) 0 0;
color: white;
font-size: 1.3em;
font-weight: 700;
}
.section-header .icon { font-size: 1.6em; }
.section-body { background: white; border-radius: 0 0 var(--border-radius) var(--border-radius); padding: 24px; box-shadow: var(--card-shadow); }
/* section colors */
.anatomy .section-header { background: linear-gradient(135deg, #1565c0, #0288d1); }
.benign .section-header { background: linear-gradient(135deg, #00695c, #00897b); }
.carcinoma .section-header { background: linear-gradient(135deg, #880e4f, #c62828); }
.staging .section-header { background: linear-gradient(135deg, #4a148c, #6a1b9a); }
.treatment .section-header { background: linear-gradient(135deg, #e65100, #f57c00); }
.special .section-header { background: linear-gradient(135deg, #1b5e20, #2e7d32); }
.pyq .section-header { background: linear-gradient(135deg, #b71c1c, #c62828); }
/* ====== CARDS ====== */
.card {
border-radius: 12px;
padding: 16px 20px;
margin-bottom: 18px;
border-left: 5px solid;
}
.card.blue { background: var(--blue-light); border-color: var(--blue); }
.card.green { background: var(--green-light); border-color: var(--teal); }
.card.pink { background: var(--pink-light); border-color: var(--pink); }
.card.orange { background: var(--orange-light); border-color: var(--orange); }
.card.purple { background: var(--purple-light); border-color: var(--purple); }
.card.red { background: var(--red-light); border-color: var(--red); }
.card.yellow { background: var(--yellow-light); border-color: var(--yellow); }
.card h4 { font-size: 1em; font-weight: 700; margin-bottom: 10px; }
.card.blue h4 { color: var(--blue); }
.card.green h4 { color: var(--teal); }
.card.pink h4 { color: var(--pink); }
.card.orange h4 { color: var(--orange); }
.card.purple h4 { color: var(--purple); }
.card.red h4 { color: var(--red); }
.card.yellow h4 { color: #795548; }
/* ====== MNEMONIC BOX ====== */
.mnemonic {
background: linear-gradient(135deg, #4a148c, #7b1fa2);
color: white;
border-radius: 14px;
padding: 18px 22px;
margin: 16px 0;
position: relative;
overflow: hidden;
box-shadow: 0 4px 16px rgba(74,20,140,0.3);
}
.mnemonic::before {
content: '🧠';
position: absolute;
right: 16px; top: 14px;
font-size: 2em;
opacity: 0.4;
}
.mnemonic .label {
font-size: 0.72em;
text-transform: uppercase;
letter-spacing: 2px;
opacity: 0.8;
margin-bottom: 6px;
font-weight: 600;
}
.mnemonic h4 { font-size: 1.05em; margin-bottom: 8px; }
.mnemonic .phrase { font-size: 1.5em; font-weight: 800; letter-spacing: 3px; color: #f8bbd0; display: block; margin-bottom: 8px; }
.mnemonic ul { padding-left: 18px; }
.mnemonic li { margin-bottom: 4px; opacity: 0.95; font-size: 0.95em; }
/* ====== TABLE ====== */
table { width: 100%; border-collapse: collapse; margin: 14px 0; font-size: 0.9em; }
thead tr { background: linear-gradient(135deg, #880e4f, #4a148c); color: white; }
thead th { padding: 10px 14px; text-align: left; font-weight: 600; }
tbody tr:nth-child(even) { background: #f5f5f5; }
tbody tr:hover { background: #fce4ec; }
td { padding: 9px 14px; border-bottom: 1px solid #e0e0e0; vertical-align: top; }
td strong { color: var(--pink); }
/* ====== PYQ BADGE ====== */
.pyq-tag {
display: inline-block;
background: linear-gradient(135deg, #b71c1c, #e53935);
color: white;
font-size: 0.7em;
font-weight: 700;
padding: 2px 10px;
border-radius: 10px;
margin-left: 8px;
vertical-align: middle;
letter-spacing: 0.5px;
}
.inicet-tag {
display: inline-block;
background: linear-gradient(135deg, #1565c0, #1e88e5);
color: white;
font-size: 0.7em;
font-weight: 700;
padding: 2px 10px;
border-radius: 10px;
margin-left: 8px;
vertical-align: middle;
}
.high-yield {
display: inline-block;
background: #ffd600;
color: #212121;
font-size: 0.7em;
font-weight: 800;
padding: 2px 10px;
border-radius: 10px;
margin-left: 6px;
}
/* ====== FLOWCHART ====== */
.flowchart {
background: white;
border: 2px solid var(--pink-mid);
border-radius: 14px;
padding: 20px;
margin: 16px 0;
text-align: center;
}
.flowchart h4 { color: var(--pink); margin-bottom: 16px; font-size: 1em; }
.flow-step {
display: inline-block;
background: var(--pink-light);
border: 2px solid var(--pink);
color: var(--red);
font-weight: 600;
padding: 8px 20px;
border-radius: 30px;
font-size: 0.88em;
margin: 4px;
}
.flow-step.blue { background: var(--blue-light); border-color: var(--blue); color: var(--blue); }
.flow-step.green { background: var(--green-light); border-color: var(--teal); color: var(--teal); }
.flow-step.orange { background: var(--orange-light); border-color: var(--orange); color: var(--orange); }
.flow-step.purple { background: var(--purple-light); border-color: var(--purple); color: var(--purple); }
.flow-step.yellow { background: var(--yellow-light); border-color: var(--yellow); color: #5d4037; }
.flow-arrow { display: block; font-size: 1.4em; color: #9e9e9e; margin: 4px 0; }
.flow-row { display: flex; justify-content: center; align-items: center; flex-wrap: wrap; gap: 6px; margin: 4px 0; }
.flow-connector { font-size: 1.2em; color: #9e9e9e; font-weight: 600; }
/* ====== DIAGRAM ====== */
.diagram-box {
background: linear-gradient(135deg, #e3f2fd, #f3e5f5);
border: 2px dashed #7986cb;
border-radius: 14px;
padding: 20px;
margin: 16px 0;
text-align: center;
}
.diagram-box h4 { color: var(--purple); margin-bottom: 14px; font-weight: 700; }
/* ====== COMPARISON BOX ====== */
.compare-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 14px; margin: 14px 0; }
.compare-box { border-radius: 12px; padding: 14px; }
.compare-box.left { background: #e8f5e9; border: 2px solid #43a047; }
.compare-box.right { background: #ffebee; border: 2px solid #e53935; }
.compare-box h5 { font-size: 0.95em; font-weight: 700; margin-bottom: 10px; }
.compare-box.left h5 { color: #1b5e20; }
.compare-box.right h5 { color: #b71c1c; }
/* ====== LIST STYLES ====== */
ul.styled { padding-left: 0; list-style: none; }
ul.styled li { padding: 5px 0 5px 24px; position: relative; border-bottom: 1px solid rgba(0,0,0,0.04); }
ul.styled li::before { content: '▸'; position: absolute; left: 6px; color: var(--pink); font-weight: 700; }
ul.tick li::before { content: '✓'; color: var(--teal); }
ul.cross li::before { content: '✗'; color: var(--red); }
ul.star li::before { content: '★'; color: var(--yellow); }
ul.warn li::before { content: '⚠'; color: var(--orange); }
/* ====== HIGHLIGHT BOX ====== */
.highlight-box {
border-radius: 12px;
padding: 14px 18px;
margin: 12px 0;
font-weight: 600;
display: flex;
align-items: flex-start;
gap: 12px;
}
.highlight-box .icon { font-size: 1.4em; flex-shrink: 0; }
.highlight-box.warning { background: #fff8e1; border: 2px solid #ffc107; color: #5d4037; }
.highlight-box.danger { background: #ffebee; border: 2px solid #f44336; color: #b71c1c; }
.highlight-box.info { background: #e3f2fd; border: 2px solid #2196f3; color: #0d47a1; }
.highlight-box.success { background: #e8f5e9; border: 2px solid #4caf50; color: #1b5e20; }
/* ====== QUICK FACT ====== */
.quick-fact {
background: linear-gradient(135deg, #ff6f00, #ff8f00);
color: white;
border-radius: 10px;
padding: 10px 16px;
margin: 10px 0;
font-size: 0.9em;
font-weight: 600;
display: flex;
gap: 10px;
align-items: flex-start;
}
/* ====== RECALL BOX ====== */
.recall-box {
background: linear-gradient(135deg, #1a237e, #283593);
color: white;
border-radius: 12px;
padding: 14px 18px;
margin: 14px 0;
}
.recall-box .label { font-size: 0.72em; text-transform: uppercase; letter-spacing: 2px; opacity: 0.7; margin-bottom: 4px; }
.recall-box p { font-size: 0.95em; line-height: 1.6; }
/* ====== PYQ SECTION ====== */
.pyq-card {
background: white;
border: 2px solid #e53935;
border-radius: 14px;
margin-bottom: 16px;
overflow: hidden;
}
.pyq-card .pyq-header {
background: linear-gradient(135deg, #b71c1c, #e53935);
color: white;
padding: 10px 18px;
font-weight: 700;
font-size: 0.85em;
display: flex;
justify-content: space-between;
align-items: center;
}
.pyq-card .pyq-q { padding: 14px 18px; font-weight: 600; line-height: 1.6; }
.pyq-card .pyq-options { padding: 0 18px 10px; }
.pyq-card .pyq-options div { padding: 5px 0; font-size: 0.92em; color: #555; }
.pyq-card .pyq-answer {
background: #e8f5e9;
border-top: 2px solid #4caf50;
padding: 12px 18px;
color: #1b5e20;
font-weight: 600;
font-size: 0.9em;
}
.correct-option { color: #1b5e20; font-weight: 700; }
/* ====== RESPONSIVE ====== */
@media (max-width: 600px) {
.compare-grid { grid-template-columns: 1fr; }
.main-header h1 { font-size: 1.5em; }
}
/* ====== PRINT ====== */
@media print {
body { background: white; }
.section-body { box-shadow: none; border: 1px solid #eee; }
.mnemonic { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
}
h2 { font-size: 1.1em; color: var(--pink); font-weight: 700; margin: 18px 0 10px; border-bottom: 2px solid var(--pink-light); padding-bottom: 4px; }
h3 { font-size: 1em; font-weight: 700; margin: 14px 0 8px; }
p { margin-bottom: 10px; }
strong { color: var(--red); }
.source { font-size: 0.75em; color: #9e9e9e; font-style: italic; margin-top: 6px; }
</style>
</head>
<body>
<!-- ======================== HEADER ======================== -->
<div class="main-header">
<div>🎀 BREAST SURGERY</div>
<h1>RAPID REVISION NOTES</h1>
<div class="subtitle">NEET PG | INICET | USMLE Oriented</div>
<div class="badges">
<span class="badge">📚 Bailey & Love 28e</span>
<span class="badge">📖 Schwartz's 11e</span>
<span class="badge">📗 Sabiston</span>
<span class="badge">🧠 PYQs Included</span>
<span class="badge">⚡ High Yield</span>
</div>
</div>
<!-- ======================== TOC ======================== -->
<div class="toc">
<h3>📋 Quick Navigation</h3>
<div class="toc-grid">
<a href="#anatomy" class="toc-item">🔬 Anatomy</a>
<a href="#andi" class="toc-item">🌱 ANDI Concept</a>
<a href="#benign" class="toc-item">🟢 Benign Conditions</a>
<a href="#fibroadenoma" class="toc-item">⚪ Fibroadenoma</a>
<a href="#abscess" class="toc-item">🔴 Breast Abscess</a>
<a href="#nipple" class="toc-item">💧 Nipple Discharge</a>
<a href="#carcinoma" class="toc-item">⚠️ Breast Carcinoma</a>
<a href="#risk" class="toc-item">🎯 Risk Factors</a>
<a href="#types" class="toc-item">🔬 Types of Cancer</a>
<a href="#staging" class="toc-item">📊 TNM Staging</a>
<a href="#treatment" class="toc-item">💊 Treatment</a>
<a href="#surgery" class="toc-item">🔪 Surgical Options</a>
<a href="#phyllodes" class="toc-item">🌿 Phyllodes Tumour</a>
<a href="#special" class="toc-item">⭐ Special Topics</a>
<a href="#pyqs" class="toc-item">❓ PYQs</a>
<a href="#mnemonics" class="toc-item">🧠 All Mnemonics</a>
</div>
</div>
<!-- ======================== SECTION 1: ANATOMY ======================== -->
<div class="section anatomy" id="anatomy">
<div class="section-header">
<span class="icon">🔬</span>
<span>SURGICAL ANATOMY OF THE BREAST</span>
<span class="pyq-tag">PYQ</span>
</div>
<div class="section-body">
<div class="card blue">
<h4>📍 Location & Boundaries</h4>
<ul class="styled">
<li><strong>Lies on:</strong> Pectoralis major (2/3) + Serratus anterior (1/3)</li>
<li><strong>Vertical extent:</strong> 2nd – 6th rib</li>
<li><strong>Horizontal extent:</strong> Lateral sternal border → Anterior axillary line</li>
<li><strong>Axillary tail of Spence</strong> — extends through foramen in deep fascia into the axilla</li>
<li><strong>Retromammary space</strong> — loose areolar tissue between breast and pectoral fascia (allows breast mobility)</li>
</ul>
</div>
<div class="diagram-box">
<h4>🗺️ Quadrants of the Breast</h4>
<svg viewBox="0 0 300 300" width="260" height="260" style="display:block;margin:auto;">
<!-- Outer circle -->
<circle cx="150" cy="150" r="120" fill="#fce4ec" stroke="#e91e63" stroke-width="2.5"/>
<!-- Crosshairs -->
<line x1="30" y1="150" x2="270" y2="150" stroke="#e91e63" stroke-width="2"/>
<line x1="150" y1="30" x2="150" y2="270" stroke="#e91e63" stroke-width="2"/>
<!-- Nipple -->
<circle cx="150" cy="150" r="14" fill="#e91e63"/>
<text x="150" y="155" text-anchor="middle" fill="white" font-size="9" font-weight="bold">Nipple</text>
<!-- Quadrant labels -->
<text x="200" y="110" text-anchor="middle" fill="#880e4f" font-size="12" font-weight="bold">UOQ</text>
<text x="200" y="123" text-anchor="middle" fill="#880e4f" font-size="9">60% cancers</text>
<text x="100" y="110" text-anchor="middle" fill="#880e4f" font-size="12" font-weight="bold">UIQ</text>
<text x="200" y="200" text-anchor="middle" fill="#880e4f" font-size="12" font-weight="bold">LOQ</text>
<text x="100" y="200" text-anchor="middle" fill="#880e4f" font-size="12" font-weight="bold">LIQ</text>
<!-- Axillary tail -->
<ellipse cx="255" cy="105" rx="28" ry="14" fill="#f8bbd0" stroke="#e91e63" stroke-width="1.5"/>
<text x="255" y="101" text-anchor="middle" fill="#880e4f" font-size="8" font-weight="bold">Axillary</text>
<text x="255" y="111" text-anchor="middle" fill="#880e4f" font-size="8" font-weight="bold">Tail of Spence</text>
<line x1="230" y1="112" x2="218" y2="128" stroke="#e91e63" stroke-width="1.5" stroke-dasharray="3"/>
</svg>
<p style="color:#880e4f;font-size:0.88em;margin-top:8px;"><strong>UOQ = Upper Outer Quadrant</strong> → Most common site of breast cancer (60%)</p>
</div>
<div class="card blue">
<h4>🩸 Blood Supply</h4>
<ul class="styled">
<li><strong>Main supply:</strong> Internal mammary artery (perforating branches — 60%)</li>
<li>Lateral thoracic artery (branch of axillary artery)</li>
<li>Thoracoacromial artery branches</li>
<li>Posterior intercostal arteries (lateral branches)</li>
</ul>
</div>
<div class="card blue">
<h4>🫀 Lymphatic Drainage</h4>
<table>
<thead><tr><th>Group</th><th>Level</th><th>Location</th><th>Notes</th></tr></thead>
<tbody>
<tr><td><strong>Anterior (Pectoral)</strong></td><td>Level I</td><td>Lateral to pectoralis minor</td><td>Principal group; receives 75% of lymph</td></tr>
<tr><td><strong>Central</strong></td><td>Level II</td><td>Behind pectoralis minor</td><td>Between levels I & III</td></tr>
<tr><td><strong>Apical (Subclavicular)</strong></td><td>Level III</td><td>Medial to pectoralis minor</td><td>Highest group; Rotter's nodes here</td></tr>
<tr><td><strong>Posterior (Subscapular)</strong></td><td>Level I</td><td>Along subscapular vessels</td><td></td></tr>
<tr><td><strong>Lateral (Brachial)</strong></td><td>Level I</td><td>Along axillary vein</td><td></td></tr>
<tr><td><strong>Parasternal</strong></td><td>—</td><td>Along internal mammary</td><td>Inner half tumours drain here (25%)</td></tr>
</tbody>
</table>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — Axillary Lymph Node Levels</div>
<h4>Axillary Lymph Node Levels by Rotter</h4>
<span class="phrase">PALM</span>
<ul>
<li><strong>P</strong>ectoral (Anterior) = Level I (Lateral to pec minor)</li>
<li><strong>A</strong>pical = Level III (Medial to pec minor)</li>
<li><strong>L</strong>ateral (Brachial) = Level I</li>
<li><strong>M</strong>iddle / Central = Level II (Behind pec minor)</li>
</ul>
<div style="margin-top:8px;font-size:0.88em;opacity:0.85;">💡 <strong>Rotter's nodes</strong> = interpectoral nodes between pec major & minor (Level IIb)</div>
</div>
<div class="card blue">
<h4>🧠 Cooper's Ligaments</h4>
<ul class="styled">
<li>Fibrous septa connecting skin → underlying pectoral fascia</li>
<li>Give structural support to breast lobules</li>
<li><strong>Skin dimpling / tethering in cancer</strong> = Cooper's ligaments invaded and shortened by tumour (desmoplastic reaction)</li>
<li>FGF released by tumour → fibrocytes → fibroblasts → lay down collagen → Cooper's ligament shortens</li>
</ul>
</div>
<div class="card blue">
<h4>🔬 Microanatomy — TDLU</h4>
<p><strong>Terminal Duct Lobular Unit (TDLU)</strong> is the functional unit of the breast and the site of origin of most breast carcinomas (both DCIS and invasive carcinoma).</p>
<p>Structure: Terminal ductule → acini/lobules → intralobular stroma</p>
</div>
<div class="source">Sources: Bailey & Love 28e, Chapter 58 | Schwartz's 11e, Chapter 17</div>
</div>
</div>
<!-- ======================== SECTION 2: ANDI ======================== -->
<div class="section benign" id="andi">
<div class="section-header">
<span class="icon">🌱</span>
<span>ANDI — ABERRATIONS OF NORMAL DEVELOPMENT AND INVOLUTION</span>
<span class="pyq-tag">NEET PG</span>
</div>
<div class="section-body">
<div class="card green">
<h4>💡 Concept (Cardiff Breast Clinic, UK)</h4>
<p>Most benign breast disorders are <strong>minor aberrations of normal physiological processes</strong> (development, cyclical change, involution) — NOT true diseases.</p>
</div>
<table>
<thead><tr><th>Phase</th><th>Age</th><th>Normal Process</th><th>Aberration (ANDI)</th><th>Disease</th></tr></thead>
<tbody>
<tr><td><strong>Development</strong></td><td>15–25 yrs</td><td>Lobule formation, stroma</td><td><strong>Fibroadenoma</strong></td><td>Giant fibroadenoma</td></tr>
<tr><td><strong>Cyclical Change</strong></td><td>15–50 yrs</td><td>Hormonal breast response</td><td>Cyclical mastalgia, nodularity</td><td>Incapacitating mastalgia</td></tr>
<tr><td><strong>Involution</strong></td><td>35–55 yrs</td><td>Duct/lobule involution</td><td><strong>Macrocysts, sclerosing adenosis</strong></td><td>Epitheliosis, ADH</td></tr>
<tr><td><strong>Duct Involution</strong></td><td>35–55 yrs</td><td>Duct shortening</td><td>Duct ectasia, nipple retraction</td><td>Periductal mastitis</td></tr>
</tbody>
</table>
<div class="mnemonic">
<div class="label">Mnemonic — ANDI phases</div>
<span class="phrase">DCI</span>
<ul>
<li><strong>D</strong>evelopment (15-25) → Fibroadenoma</li>
<li><strong>C</strong>yclical Change (15-50) → Mastalgia, Nodularity</li>
<li><strong>I</strong>nvolution (35-55) → Cysts, Duct ectasia</li>
</ul>
</div>
<h2>Epithelial Hyperplasia & Cancer Risk</h2>
<div class="card green">
<h4>Relative Risk of Cancer (RR)</h4>
<table>
<thead><tr><th>Pathology</th><th>Relative Risk</th><th>Notes</th></tr></thead>
<tbody>
<tr><td>No proliferative change</td><td><strong>1.0</strong></td><td>Baseline</td></tr>
<tr><td>Proliferative disease WITHOUT atypia</td><td><strong>1.5–2×</strong></td><td>UDH, papilloma, sclerosing adenosis</td></tr>
<tr><td>Atypical Ductal Hyperplasia (ADH)</td><td><strong>4–5×</strong></td><td>+Family Hx → 10× risk</td></tr>
<tr><td>Atypical Lobular Hyperplasia (ALH)</td><td><strong>4–5×</strong></td><td>Bilateral marker of risk</td></tr>
<tr><td>LCIS (Lobular carcinoma in situ)</td><td><strong>8–10×</strong></td><td>Bilateral risk marker</td></tr>
<tr><td>DCIS</td><td><strong>8–10×</strong></td><td>Local precursor</td></tr>
<tr><td>Solitary intraductal papilloma</td><td><strong>1.5–2×</strong></td><td></td></tr>
<tr><td>Papillomatosis (>5 papillomas)</td><td><strong>3×</strong></td><td></td></tr>
</tbody>
</table>
</div>
<div class="source">Source: Bailey & Love 28e, p.940-941</div>
</div>
</div>
<!-- ======================== SECTION 3: BENIGN ======================== -->
<div class="section benign" id="benign">
<div class="section-header">
<span class="icon">🟢</span>
<span>BENIGN BREAST DISEASE</span>
<span class="pyq-tag">PYQ</span>
<span class="inicet-tag">INICET</span>
</div>
<div class="section-body" id="fibroadenoma">
<h2>🔵 Fibroadenoma</h2>
<div class="card green">
<h4>Key Features</h4>
<ul class="styled">
<li><strong>Most common benign tumour</strong> of the breast in women <30 years</li>
<li>Origin: <strong>TDLU</strong> (lobular development phase)</li>
<li>Oestrogen-sensitive (grows in pregnancy, regresses in menopause)</li>
<li>Well-encapsulated <em>fibroepithelial</em> tumour — both stroma AND epithelium</li>
</ul>
</div>
<div class="compare-grid">
<div class="compare-box left">
<h5>✅ Clinical Features</h5>
<ul class="styled tick">
<li>Smooth, rounded, lobulated lump</li>
<li><strong>"Breast mouse"</strong> — highly mobile</li>
<li>Rubbery / firm consistency</li>
<li>Non-tender (usually)</li>
<li>Typically solitary; 20% multiple</li>
<li>Most common in UOQ</li>
</ul>
</div>
<div class="compare-box right">
<h5>🔬 Histology Types</h5>
<ul class="styled">
<li><strong>Intracanalicular</strong> — stroma compresses ducts into clefts</li>
<li><strong>Pericanalicular</strong> — stroma grows concentrically around ducts</li>
<li>(Both types coexist; distinction has no clinical relevance)</li>
</ul>
</div>
</div>
<div class="card green">
<h4>🔬 Giant Fibroadenoma</h4>
<ul class="styled">
<li>Size > 5 cm (some define as >500 g)</li>
<li>Common in <strong>adolescent girls</strong> and <strong>African women</strong></li>
<li>Excision via <strong>submammary (Gaillard Thomas) incision</strong></li>
</ul>
</div>
<div class="flowchart">
<h4>🔄 Management Flowchart — Fibroadenoma</h4>
<div class="flow-step blue">Palpable breast lump in <30 yr woman</div>
<span class="flow-arrow">↓</span>
<div class="flow-step">Triple Assessment</div>
<span class="flow-arrow">↓</span>
<div class="flow-row">
<div class="flow-step blue">Clinical Exam</div>
<span class="flow-connector">+</span>
<div class="flow-step orange">Ultrasound</div>
<span class="flow-connector">+</span>
<div class="flow-step purple">Core Needle Biopsy</div>
</div>
<span class="flow-arrow">↓</span>
<div class="flow-row">
<div class="flow-step green">BI-RADS 2 / 3 + <3cm + age <25</div>
<span class="flow-connector" style="margin:0 12px;">OR</span>
<div class="flow-step">BI-RADS 4+ / size >4cm / growing</div>
</div>
<span class="flow-arrow">↓ ↓</span>
<div class="flow-row">
<div class="flow-step green">Conservative / Annual USS</div>
<div class="flow-step">Surgical Excision</div>
</div>
</div>
<h2>🔵 Breast Cysts</h2>
<div class="card green">
<h4>Key Points</h4>
<ul class="styled">
<li>Peak age: <strong>35–55 years</strong> (peri-menopausal)</li>
<li>Part of <strong>involution phase of ANDI</strong></li>
<li>May be multiple, bilateral; can mimic malignancy</li>
<li>Present suddenly causing alarm; resolved with USS-guided aspiration</li>
<li><strong>Smooth-walled cyst</strong> = BI-RADS 2 → Observation only</li>
<li><strong>Complex cyst</strong> (solid component in wall) → Core biopsy (exclude cystadenocarcinoma)</li>
<li><strong>Complicated cyst</strong> = intracystic floating debris that moves with posture change</li>
</ul>
</div>
<h2>🔵 Galactocele</h2>
<div class="card green">
<ul class="styled">
<li>Rare milk-filled cyst — during/after <strong>lactation</strong></li>
<li>Subareolar location</li>
<li>Treatment: <strong>Single aspiration</strong> (usually curative); rarely surgical excision</li>
<li><strong>Encourage breastfeeding</strong> to continue</li>
</ul>
</div>
<h2>🔵 Mastalgia (Breast Pain)</h2>
<div class="compare-grid">
<div class="compare-box left">
<h5>Cyclical Mastalgia</h5>
<ul class="styled">
<li>Premenstrual; bilateral</li>
<li>Upper outer quadrant</li>
<li>Oestrogen related</li>
<li>Tx: <strong>Evening Primrose Oil</strong> (GLA), Danazol, Tamoxifen</li>
</ul>
</div>
<div class="compare-box right">
<h5>Non-Cyclical Mastalgia</h5>
<ul class="styled">
<li>Unrelated to cycle; unilateral</li>
<li>Constant or intermittent</li>
<li>Causes: Sclerosing adenosis, duct ectasia</li>
<li>Tx: NSAIDs, reassurance</li>
</ul>
</div>
</div>
<div class="source">Source: Bailey & Love 28e, pp.940–945</div>
</div>
</div>
<!-- ======================== NIPPLE DISCHARGE ======================== -->
<div class="section benign" id="nipple">
<div class="section-header">
<span class="icon">💧</span>
<span>NIPPLE DISCHARGE</span>
<span class="pyq-tag">PYQ</span>
</div>
<div class="section-body">
<div class="diagram-box">
<h4>💧 Types of Nipple Discharge — Diagnostic Chart</h4>
<table>
<thead><tr><th>Type</th><th>Single Duct</th><th>Multiple Ducts</th><th>Cause</th></tr></thead>
<tbody>
<tr>
<td><strong>Bloodstained</strong> <span class="pyq-tag">PYQ</span></td>
<td>Intraductal papilloma <strong>(MC)</strong>, Intraductal carcinoma, Duct ectasia</td>
<td>Carcinoma, Duct ectasia</td>
<td><strong>Papilloma = MC cause of bloody nipple discharge</strong></td>
</tr>
<tr>
<td><strong>Serous (sticky)</strong></td>
<td>Duct papilloma, Ductal hyperplasia, Duct ectasia, DCIS</td>
<td>—</td>
<td>Benign usually</td>
</tr>
<tr>
<td><strong>Black / Green / Muddy</strong></td>
<td>—</td>
<td>Duct ectasia</td>
<td>Duct ectasia (MC)</td>
</tr>
<tr>
<td><strong>Purulent</strong></td>
<td>—</td>
<td>Periductal mastitis</td>
<td>Infection</td>
</tr>
<tr>
<td><strong>Milky (galactorrhoea)</strong></td>
<td>Both</td>
<td>Lactation, Prolactinoma, Hypothyroidism, Drugs</td>
<td>Prolactin-related</td>
</tr>
<tr>
<td><strong>Surface (not from duct)</strong></td>
<td>—</td>
<td>Paget's disease, Eczema, Psoriasis</td>
<td>Skin lesion</td>
</tr>
</tbody>
</table>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — Causes of Bloody Nipple Discharge</div>
<span class="phrase">DICED</span>
<ul>
<li><strong>D</strong>uctal papilloma (MC — 75%)</li>
<li><strong>I</strong>ntraductal carcinoma (DCIS)</li>
<li><strong>C</strong>arcinoma (invasive)</li>
<li><strong>E</strong>ctasia of ducts</li>
<li><strong>D</strong>uctal hyperplasia</li>
</ul>
</div>
<h2>Management of Nipple Discharge</h2>
<div class="flowchart">
<h4>💧 Management Flowchart</h4>
<div class="flow-step">Nipple Discharge</div>
<span class="flow-arrow">↓</span>
<div class="flow-step blue">Triple Assessment (Clinical + USS + Biopsy)</div>
<span class="flow-arrow">↓</span>
<div class="flow-row">
<div class="flow-step green">Non-bloody + Normal triple</div>
<span class="flow-connector" style="margin:0 10px;">|</span>
<div class="flow-step orange">Age <40 + Blood + Normal triple</div>
<span class="flow-connector" style="margin:0 10px;">|</span>
<div class="flow-step">Age >40 + Blood / Single duct</div>
</div>
<span class="flow-arrow">↓ ↓ ↓</span>
<div class="flow-row">
<div class="flow-step green">Reassure</div>
<div class="flow-step orange">Reassure + Annual imaging</div>
<div class="flow-step purple">Microdochectomy (single) OR Hadfield's (multi-duct)</div>
</div>
</div>
<div class="card green">
<h4>🔪 Surgical Procedures</h4>
<ul class="styled">
<li><strong>Microdochectomy:</strong> Excision of 1.5–2 cm of single affected duct; for single duct discharge</li>
<li><strong>Hadfield's Major Mammary Duct Excision:</strong> Excision of 5 cm cone of major ducts from nipple; for multiduct discharge; also for duct ectasia + periductal mastitis</li>
<li>Most intraductal papillomas within <strong>5 cm of the nipple</strong></li>
</ul>
</div>
<div class="source">Source: Bailey & Love 28e, pp.946–947</div>
</div>
</div>
<!-- ======================== BREAST ABSCESS ======================== -->
<div class="section benign" id="abscess">
<div class="section-header">
<span class="icon">🔴</span>
<span>BREAST ABSCESS & MASTITIS</span>
<span class="pyq-tag">NEET PG</span>
</div>
<div class="section-body">
<div class="compare-grid">
<div class="compare-box left">
<h5>🤱 Lactational (Puerperal) Mastitis / Abscess</h5>
<ul class="styled">
<li>First 3 weeks postpartum</li>
<li><strong>Organism: Staph. aureus (MC)</strong></li>
<li>Entry through cracked nipple</li>
<li>Peripheral location in breast</li>
<li>Tx: Antibiotics (flucloxacillin/co-amoxiclav) + Continue breastfeeding</li>
<li>If abscess: USS-guided <strong>needle aspiration</strong> (preferred) or incision & drainage</li>
<li>Incision: <strong>Radial incision</strong> in peripheral abscess</li>
</ul>
</div>
<div class="compare-box right">
<h5>🚭 Non-Lactational / Periductal Mastitis</h5>
<ul class="styled">
<li>Young non-pregnant women; <strong>smokers</strong></li>
<li><strong>Subareolar location</strong></li>
<li>Mixed anaerobic + aerobic organisms</li>
<li>Associated with <strong>mammary duct fistula</strong></li>
<li>Tx: Antibiotics + aspiration</li>
<li>If abscess/fistula: <strong>Hadfield's duct excision</strong></li>
<li>Incision: <strong>Circumareolar incision</strong></li>
<li>Smoking cessation is key to prevent recurrence</li>
</ul>
</div>
</div>
<div class="card orange">
<h4>⚠️ Mammary Duct Fistula (Zuska's Disease)</h4>
<ul class="styled">
<li>Abnormal communication between subareolar duct & skin near areola</li>
<li>Complication of non-lactational periductal mastitis</li>
<li>Treatment: <strong>Fistula excision + Hadfield's major duct excision</strong></li>
<li>Associated with: <strong>Smoking</strong>, squamous metaplasia of duct epithelium</li>
</ul>
</div>
<div class="card orange">
<h4>🦠 Idiopathic Granulomatous Mastitis (IGM)</h4>
<ul class="styled">
<li>Young parous women within <strong>first few years post-pregnancy</strong></li>
<li>Associated with <em>Corynebacterium kroppenstedtii</em></li>
<li>Mimics cancer (peau d'orange, nipple retraction, axillary lymphadenopathy)</li>
<li>Histology: <strong>Non-caseating granuloma</strong> with chronic inflammation</li>
<li>Biopsy: excludes TB, foreign body, sarcoidosis</li>
<li>Tx: NSAIDs + antibiotics + steroids; surgical drainage if needed</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — Breast Abscess Key Points</div>
<span class="phrase">SLAP</span>
<ul>
<li><strong>S</strong>taph aureus = MC organism in lactational</li>
<li><strong>L</strong>actational = Peripheral; Non-Lactational = Subareolar</li>
<li><strong>A</strong>spiration under USS guidance = preferred Tx</li>
<li><strong>P</strong>eriductal mastitis → Hadfield's + Stop smoking</li>
</ul>
</div>
<div class="source">Source: Bailey & Love 28e, pp.948–950</div>
</div>
</div>
<!-- ======================== BREAST CARCINOMA ======================== -->
<div class="section carcinoma" id="carcinoma">
<div class="section-header">
<span class="icon">⚠️</span>
<span>CARCINOMA OF THE BREAST</span>
<span class="pyq-tag">HIGH YIELD</span>
</div>
<div class="section-body" id="risk">
<div class="card red">
<h4>📊 Epidemiology</h4>
<ul class="styled">
<li><strong>Most common cancer</strong> in women worldwide</li>
<li><strong>2nd most common cause</strong> of cancer death in women (after lung cancer)</li>
<li>UOQ most common site: <strong>60% of breast cancers</strong></li>
<li>Bilateral breast cancer in 1–2% of cases</li>
<li>Left breast more common than right breast (slight predominance)</li>
</ul>
</div>
<h2>🎯 Risk Factors for Breast Cancer</h2>
<table>
<thead><tr><th>Category</th><th>Risk Factor</th><th>RR</th><th>Notes</th></tr></thead>
<tbody>
<tr><td rowspan="5"><strong>Hormonal (↑ Oestrogen)</strong></td><td>Early menarche (<12 yr)</td><td>↑</td><td></td></tr>
<tr><td>Late menopause (>55 yr)</td><td>↑</td><td></td></tr>
<tr><td>Nulliparity / Late 1st pregnancy (>35 yr)</td><td>↑</td><td></td></tr>
<tr><td>No breastfeeding</td><td>↑</td><td></td></tr>
<tr><td>HRT (oestrogen + progestogen)</td><td><strong>2×</strong></td><td>Ceases on stopping HRT</td></tr>
<tr><td rowspan="4"><strong>Genetic</strong></td><td>BRCA1 mutation</td><td><strong>65–80%</strong> lifetime risk</td><td>Also ↑ ovarian Ca risk</td></tr>
<tr><td>BRCA2 mutation</td><td><strong>45–85%</strong> lifetime risk</td><td>Also male breast Ca</td></tr>
<tr><td>1st degree family history (1 relative)</td><td><strong>2×</strong></td><td></td></tr>
<tr><td>1st degree (bilateral / young)</td><td><strong>4–6×</strong></td><td></td></tr>
<tr><td rowspan="3"><strong>Previous disease</strong></td><td>Previous breast cancer</td><td><strong>5×</strong></td><td></td></tr>
<tr><td>ADH</td><td><strong>4–5×</strong></td><td></td></tr>
<tr><td>LCIS</td><td><strong>8–10×</strong></td><td>Bilateral marker</td></tr>
<tr><td rowspan="3"><strong>Other</strong></td><td>Radiation exposure (mantle RT)</td><td>↑</td><td></td></tr>
<tr><td>Obesity (post-menopausal)</td><td>↑</td><td>↑ peripheral oestrogen conversion</td></tr>
<tr><td>High alcohol intake</td><td>↑</td><td>Dose-dependent</td></tr>
</tbody>
</table>
<div class="card red">
<h4>🧬 BRCA Mutations — High Yield Points</h4>
<ul class="styled">
<li><strong>BRCA1</strong> (Chr 17q): DNA repair; → breast Ca (65–80%), ovarian Ca (35–46%), triple-negative breast Ca</li>
<li><strong>BRCA2</strong> (Chr 13q): DNA repair; → breast Ca (45–85%), male breast Ca (6%), ovarian Ca (10–20%)</li>
<li>Testing offered if: ≥10% probability based on family history</li>
<li><strong>Prophylactic mastectomy</strong> reduces risk by 90%</li>
<li><strong>Tamoxifen</strong> (pre-menopausal) or <strong>Aromatase inhibitors</strong> (post-menopausal) for chemoprevention</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — Protective Factors in Breast Cancer</div>
<span class="phrase">BREASTFEED</span>
<ul>
<li><strong>B</strong>reastfeeding (lactation suppresses ovulation)</li>
<li><strong>R</strong>egular exercise</li>
<li><strong>E</strong>arly first full-term pregnancy (<20 yr)</li>
<li><strong>A</strong>spirin / NSAIDs (mild protection)</li>
<li><strong>S</strong>elective oestrogen receptor modulators (Tamoxifen)</li>
<li><strong>T</strong>hinness (low BMI)</li>
<li><strong>F</strong>ew menstrual cycles</li>
<li><strong>E</strong>arly menopause</li>
<li><strong>E</strong>xtirpation (oophorectomy)</li>
<li><strong>D</strong>iet (Mediterranean, low fat)</li>
</ul>
</div>
<div class="source">Source: Schwartz's 11e, Chapter 17 | Bailey & Love 28e</div>
</div>
</div>
<!-- ======================== TYPES OF BREAST CANCER ======================== -->
<div class="section carcinoma" id="types">
<div class="section-header">
<span class="icon">🔬</span>
<span>HISTOPATHOLOGY OF BREAST CANCER</span>
<span class="pyq-tag">NEET PG</span>
<span class="inicet-tag">INICET</span>
</div>
<div class="section-body">
<div class="card red">
<h4>📋 Classification (Foote & Stewart)</h4>
<table>
<thead><tr><th>#</th><th>Type</th><th>Frequency</th><th>Key Points</th></tr></thead>
<tbody>
<tr><td>1</td><td><strong>Invasive Ductal Carcinoma (NST/NOS)</strong></td><td><strong>80%</strong></td><td>Scirrhous; worst prognosis among common types; Gritty consistency; hard lump</td></tr>
<tr><td>2</td><td><strong>Invasive Lobular Carcinoma</strong></td><td><strong>10%</strong></td><td>"Indian file" pattern; bilateral (10–20%); LCIS association; ER+ usually</td></tr>
<tr><td>3</td><td><strong>Medullary Carcinoma</strong></td><td>4%</td><td>Soft, well-circumscribed; BRCA1 associated; BETTER prognosis than NST</td></tr>
<tr><td>4</td><td><strong>Mucinous (Colloid) Carcinoma</strong></td><td>2%</td><td>Elderly women; gelatinous; BEST prognosis; ER+</td></tr>
<tr><td>5</td><td><strong>Papillary Carcinoma</strong></td><td>2%</td><td>Older women; subareolar; bloody discharge; good prognosis</td></tr>
<tr><td>6</td><td><strong>Tubular Carcinoma</strong></td><td>2%</td><td>Well-differentiated; excellent prognosis; screen-detected</td></tr>
<tr><td>7</td><td><strong>Paget's Disease of Nipple</strong></td><td>1-3%</td><td>Paget cells; associated with DCIS/invasive Ca; see below</td></tr>
<tr><td>8</td><td><strong>Inflammatory Carcinoma</strong></td><td>1-4%</td><td>Worst prognosis; see below</td></tr>
</tbody>
</table>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — Prognosis of Special Types (Best → Worst)</div>
<span class="phrase">TMPMI</span>
<ul>
<li><strong>T</strong>ubular = best prognosis</li>
<li><strong>M</strong>ucinous (Colloid) = excellent</li>
<li><strong>P</strong>apillary = good</li>
<li><strong>M</strong>edullary = intermediate (better than NST)</li>
<li><strong>I</strong>nfiltrating ductal (NST) = worst among common</li>
<li>⚠️ <strong>Inflammatory</strong> = absolute worst (overall)</li>
</ul>
</div>
<h2>Paget's Disease of the Nipple</h2>
<div class="card red">
<h4>Key Points</h4>
<ul class="styled">
<li>Described by <strong>Sir James Paget in 1874</strong></li>
<li>Chronic eczematous eruption of the nipple (weeping → ulceration)</li>
<li>Pathognomonic: <strong>Paget cells</strong> — large, pale, vacuolated cells in rete pegs of epithelium</li>
<li>Almost always associated with underlying <strong>DCIS</strong> ± invasive cancer</li>
<li>Differentiate from <strong>melanoma</strong>: Paget's = CEA positive; Melanoma = S-100 positive</li>
<li>Treatment: Lumpectomy or mastectomy depending on extent</li>
</ul>
</div>
<h2>Inflammatory Breast Carcinoma</h2>
<div class="card red">
<h4>Worst Prognosis — High Yield <span class="pyq-tag">PYQ</span></h4>
<ul class="styled">
<li>Erythema + oedema involving ><strong>1/3 of breast</strong></li>
<li><strong>Peau d'orange</strong> — lymphatic permeation → skin oedema</li>
<li>No actual inflammation histologically; mimics infection</li>
<li><strong>Dermal lymphatic invasion</strong> by tumour cells = hallmark</li>
<li>5-year survival: <strong>~30–40%</strong> (Stage IIIB)</li>
<li>Treatment: <strong>Neoadjuvant chemotherapy FIRST</strong> → Surgery → RT</li>
<li><strong>Immediate reconstruction CONTRAINDICATED</strong></li>
<li>Mastectomy (not BCS); no skin or nipple sparing</li>
</ul>
</div>
<h2>DCIS vs LCIS</h2>
<div class="compare-grid">
<div class="compare-box left">
<h5>DCIS (Ductal Carcinoma In Situ)</h5>
<ul class="styled">
<li>Intraductal proliferation, no basement membrane invasion</li>
<li>Localised (not bilateral marker)</li>
<li>Screen-detected: microcalcifications on mammography</li>
<li>Comedo DCIS = central necrosis → calcifications</li>
<li>Treatment: Excision ± RT ± Tamoxifen</li>
<li>If left untreated: 30–50% → invasive Ca in 10 yrs</li>
</ul>
</div>
<div class="compare-box right">
<h5>LCIS (Lobular Carcinoma In Situ)</h5>
<ul class="styled">
<li>E-cadherin negative (key differentiator)</li>
<li><strong>Bilateral marker of risk</strong> (not a precursor per se)</li>
<li>Incidental finding; pre-menopausal</li>
<li>RR = 8–10× for BOTH breasts</li>
<li>Treatment: Close surveillance ± chemoprevention</li>
<li>No surgical excision generally needed</li>
</ul>
</div>
</div>
<div class="card red">
<h4>Molecular Subtypes of Breast Cancer</h4>
<table>
<thead><tr><th>Subtype</th><th>ER</th><th>PR</th><th>HER2</th><th>Treatment</th><th>Prognosis</th></tr></thead>
<tbody>
<tr><td><strong>Luminal A</strong></td><td>+</td><td>+</td><td>-</td><td>Hormone therapy</td><td>Best</td></tr>
<tr><td><strong>Luminal B</strong></td><td>+</td><td>±</td><td>+/-</td><td>Hormone ± chemo</td><td>Moderate</td></tr>
<tr><td><strong>HER2-enriched</strong></td><td>-</td><td>-</td><td>+</td><td>Trastuzumab + chemo</td><td>Poor without targeted Tx</td></tr>
<tr><td><strong>Triple Negative</strong></td><td>-</td><td>-</td><td>-</td><td>Chemotherapy only</td><td>Worst</td></tr>
</tbody>
</table>
<p style="margin-top:8px;"><strong>Triple Negative Breast Cancer</strong> → Associated with <strong>BRCA1</strong> mutation; basal-like; young women; aggressive behaviour</p>
</div>
<div class="card red">
<h4>🔬 Spread of Breast Cancer</h4>
<ul class="styled">
<li><strong>Local spread:</strong> Skin (dimpling via Cooper's ligaments), pectoralis major, chest wall</li>
<li><strong>Lymphatic:</strong> Axillary nodes (main) → supraclavicular; Inner half → internal mammary nodes</li>
<li><strong>Haematogenous:</strong> Bone (lumbar vertebrae > femoral neck > thoracic vertebrae > ribs > skull), liver, lung, brain</li>
<li>Bony mets usually <strong>osteolytic</strong> (osteosclerotic in breast > prostate)</li>
<li>Limb mets: <strong>above elbow and above knee</strong> (haematopoietic marrow)</li>
</ul>
</div>
<div class="source">Source: Schwartz's 11e, pp.587–603 | Bailey & Love 28e, pp.950–960</div>
</div>
</div>
<!-- ======================== STAGING ======================== -->
<div class="section staging" id="staging">
<div class="section-header">
<span class="icon">📊</span>
<span>TNM STAGING OF BREAST CANCER (AJCC 8th Ed)</span>
<span class="pyq-tag">HIGH YIELD</span>
</div>
<div class="section-body">
<div class="card purple">
<h4>🎯 T — Primary Tumour</h4>
<table>
<thead><tr><th>Stage</th><th>Size</th><th>Notes</th></tr></thead>
<tbody>
<tr><td><strong>Tx</strong></td><td colspan="2">Cannot be assessed</td></tr>
<tr><td><strong>T0</strong></td><td colspan="2">No evidence of primary tumour</td></tr>
<tr><td><strong>Tis</strong></td><td colspan="2">DCIS / LCIS / Paget's (no tumour)</td></tr>
<tr><td><strong>T1</strong></td><td>≤ 2 cm</td><td>T1mic ≤1mm, T1a 1-5mm, T1b 5-10mm, T1c 10-20mm</td></tr>
<tr><td><strong>T2</strong></td><td>>2 cm – ≤5 cm</td><td></td></tr>
<tr><td><strong>T3</strong></td><td>>5 cm</td><td></td></tr>
<tr><td><strong>T4</strong></td><td>Any size</td><td>T4a: chest wall; T4b: skin (ulcer/peau d'orange); T4c: both; T4d: Inflammatory</td></tr>
</tbody>
</table>
</div>
<div class="card purple">
<h4>🫀 N — Regional Lymph Nodes</h4>
<table>
<thead><tr><th>Stage</th><th>Nodal Status</th></tr></thead>
<tbody>
<tr><td><strong>N0</strong></td><td>No regional LN metastasis</td></tr>
<tr><td><strong>N1</strong></td><td>Metastasis in 1–3 ipsilateral axillary LNs (Level I/II) movable</td></tr>
<tr><td><strong>N2</strong></td><td>Metastasis in 4–9 axillary LNs OR internal mammary LNs (clinically apparent)</td></tr>
<tr><td><strong>N3</strong></td><td>≥10 axillary LNs OR infraclavicular OR supraclavicular LNs</td></tr>
</tbody>
</table>
<div class="highlight-box info" style="margin-top:10px;">
<span class="icon">ℹ️</span>
<span><strong>Supraclavicular LN involvement</strong> = N3 (Stage III) — No longer Stage IV in AJCC 8th edition. <span class="pyq-tag">PYQ</span></span>
</div>
</div>
<div class="card purple">
<h4>💊 Clinical Staging</h4>
<table>
<thead><tr><th>Stage</th><th>T</th><th>N</th><th>M</th><th>5-yr Survival</th></tr></thead>
<tbody>
<tr><td><strong>Stage 0</strong></td><td>Tis</td><td>N0</td><td>M0</td><td>~100%</td></tr>
<tr><td><strong>Stage I</strong></td><td>T1</td><td>N0</td><td>M0</td><td>~99%</td></tr>
<tr><td><strong>Stage IIA</strong></td><td>T0-1/N1 or T2/N0</td><td>—</td><td>M0</td><td>~93%</td></tr>
<tr><td><strong>Stage IIB</strong></td><td>T2/N1 or T3/N0</td><td>—</td><td>M0</td><td>~75%</td></tr>
<tr><td><strong>Stage IIIA</strong></td><td>T3/N1-2 or T0-3/N2</td><td>—</td><td>M0</td><td>~46%</td></tr>
<tr><td><strong>Stage IIIB</strong></td><td>T4, any N</td><td>—</td><td>M0</td><td>~41%</td></tr>
<tr><td><strong>Stage IV</strong></td><td>Any T</td><td>Any N</td><td>M1</td><td>~15–24%</td></tr>
</tbody>
</table>
</div>
<div class="mnemonic">
<div class="label">Mnemonic — T staging sizes</div>
<span class="phrase">0 → 2 → 5 → BIG</span>
<ul>
<li>T1 = ≤<strong>2</strong> cm</li>
<li>T2 = 2–<strong>5</strong> cm</li>
<li>T3 = ><strong>5</strong> cm</li>
<li>T4 = Any size + <strong>chest wall / skin involvement</strong></li>
</ul>
</div>
<div class="card purple">
<h4>🏥 Haagensen & Stout Criteria — Inoperability (Historical)</h4>
<ul class="styled warn">
<li>Extensive skin oedema (>1/3 of breast) — "en cuirasse"</li>
<li>Satellite skin nodules</li>
<li>Inflammatory breast cancer (peau d'orange)</li>
<li>Parasternal tumour nodule</li>
<li>Supraclavicular node involvement (now N3)</li>
<li>Arm oedema (lymph node involvement above clavicle)</li>
<li>Distant metastasis</li>
</ul>
</div>
<div class="source">Source: Schwartz's 11e, Table 17-10 | Bailey & Love 28e</div>
</div>
</div>
<!-- ======================== TREATMENT ======================== -->
<div class="section treatment" id="treatment">
<div class="section-header">
<span class="icon">💊</span>
<span>TREATMENT OF BREAST CANCER</span>
<span class="pyq-tag">NEET PG</span>
<span class="inicet-tag">INICET</span>
</div>
<div class="section-body" id="surgery">
<h2>Surgical Treatment</h2>
<div class="card orange">
<h4>🔪 Types of Mastectomy</h4>
<table>
<thead><tr><th>Operation</th><th>What is Removed</th><th>Notes</th></tr></thead>
<tbody>
<tr><td><strong>Lumpectomy / WLE</strong></td><td>Tumour + 1 cm margins</td><td>Part of BCS; ≤20% breast volume</td></tr>
<tr><td><strong>Simple (Total) Mastectomy</strong></td><td>Entire breast; NO axillary dissection</td><td>For prophylactic, DCIS, palliation</td></tr>
<tr><td><strong>Modified Radical Mastectomy (MRM)</strong> <span class="pyq-tag">PYQ</span></td><td>Entire breast + Level I, II, III axillary nodes + pectoral fascia</td><td><strong>Standard operation for operable breast cancer</strong>; pectoralis major preserved</td></tr>
<tr><td><strong>Radical Mastectomy (Halsted)</strong></td><td>Breast + pectoralis major + pectoralis minor + ALL axillary nodes</td><td>Historical; rarely done now</td></tr>
<tr><td><strong>Extended Radical (Urban)</strong></td><td>Halsted + internal mammary nodes</td><td>Historical only</td></tr>
<tr><td><strong>Skin-Sparing Mastectomy</strong></td><td>Breast + areola-nipple complex</td><td>For immediate reconstruction</td></tr>
<tr><td><strong>Nipple-Sparing Mastectomy</strong></td><td>Breast tissue only; skin + nipple-areola preserved</td><td>Tumour >2 cm from nipple; DCIS/Stage I-II</td></tr>
</tbody>
</table>
</div>
<div class="highlight-box warning">
<span class="icon">⚠️</span>
<span><strong>PATEY's MRM</strong> — pectoralis minor removed, pec major preserved. <strong>AUCHINCLOSS MRM</strong> — both muscles preserved. Both are MRM variants. <span class="pyq-tag">PYQ</span></span>
</div>
<h2>Breast Conservation Surgery (BCS/BCT)</h2>
<div class="card orange">
<h4>BCS = Lumpectomy + Radiotherapy (= Breast Conservation THERAPY)</h4>
<div class="compare-grid">
<div class="compare-box left">
<h5>✅ Indications (BCS Suitable)</h5>
<ul class="styled tick">
<li>T1, T2 tumours</li>
<li>Single tumour</li>
<li>Good tumour-to-breast ratio</li>
<li>Negative margins achievable</li>
</ul>
</div>
<div class="compare-box right">
<h5>✗ Contraindications to BCS</h5>
<ul class="styled cross">
<li>Multicentric tumour</li>
<li>Diffuse microcalcifications on mammogram</li>
<li>Large tumour-to-breast ratio</li>
<li>Positive margins after 2× re-excision</li>
<li>Previous breast/chest wall RT</li>
<li>SLE / Collagen vascular disease</li>
<li>Ankylosing spondylitis</li>
<li>Severe orthopnoea (cannot lie on RT table)</li>
<li>Inflammatory breast cancer</li>
<li>Pregnancy (1st/2nd trimester — RT hazard)</li>
</ul>
</div>
</div>
</div>
<h2>Sentinel Lymph Node Biopsy (SLNB)</h2>
<div class="card orange">
<h4>Key Points <span class="pyq-tag">PYQ</span></h4>
<ul class="styled">
<li><strong>First node</strong> receiving lymph from the tumour</li>
<li>Identified by: <strong>Blue dye (isosulfan / patent blue)</strong> + <strong>Technetium-99m labelled nanocolloid</strong> (radioisotope)</li>
<li>Combined technique = >95% identification rate</li>
<li>If SLN negative → no axillary dissection needed (avoids lymphoedema)</li>
<li>If SLN positive (1–2 macro mets, low tumour burden) → Can avoid ALND if proceeding to BCS + RT (ACOSOG Z0011 trial)</li>
<li>Contraindications: Clinically node-positive, prior axillary surgery, inflammatory breast Ca</li>
</ul>
</div>
<h2>Adjuvant Systemic Therapy</h2>
<table>
<thead><tr><th>Type</th><th>Drug/Treatment</th><th>Indication</th><th>Notes</th></tr></thead>
<tbody>
<tr>
<td><strong>Hormone Therapy (ER+)</strong></td>
<td><strong>Tamoxifen</strong></td>
<td>Pre-menopausal ER+</td>
<td>SERM; 5–10 years; SE: VTE, endometrial Ca, hot flushes</td>
</tr>
<tr>
<td><strong>Hormone Therapy</strong></td>
<td><strong>Aromatase Inhibitors</strong> (Anastrozole, Letrozole, Exemestane)</td>
<td>Post-menopausal ER+</td>
<td>Block peripheral oestrogen synthesis; SE: osteoporosis, arthralgia</td>
</tr>
<tr>
<td><strong>Anti-HER2</strong></td>
<td><strong>Trastuzumab (Herceptin)</strong></td>
<td>HER2 overexpression (3+ IHC or FISH+)</td>
<td>1 year IV; SE: cardiotoxicity (↓ EF)</td>
</tr>
<tr>
<td><strong>Anti-HER2</strong></td>
<td><strong>Pertuzumab</strong></td>
<td>HER2+ neoadjuvant / adjuvant</td>
<td>With trastuzumab + taxane</td>
</tr>
<tr>
<td><strong>CDK4/6 inhibitor</strong></td>
<td><strong>Palbociclib, Ribociclib</strong></td>
<td>HR+/HER2- metastatic</td>
<td>With aromatase inhibitor</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td>AC-T / FEC-D / CMF</td>
<td>Node+, ER-, HER2-, high grade</td>
<td>Anthracyclines + Taxanes (preferred)</td>
</tr>
<tr>
<td><strong>Radiation Therapy</strong></td>
<td>Post-lumpectomy (always), Post-MRM (if T3/4, ≥4 nodes+)</td>
<td>All BCS; high-risk post-MRM</td>
<td>Reduces local recurrence by 75%</td>
</tr>
<tr>
<td><strong>PARP Inhibitors</strong></td>
<td>Olaparib, Talazoparib</td>
<td>BRCA1/2 mutant metastatic TNBC</td>
<td>Approved in BRCA-mutated HER2-</td>
</tr>
</tbody>
</table>
<div class="flowchart">
<h4>🔄 Treatment Flowchart — Operable Breast Cancer (Stage I-III)</h4>
<div class="flow-step blue">BIOPSY (Core needle / Trucut) → Diagnosis confirmed</div>
<span class="flow-arrow">↓</span>
<div class="flow-step">Staging: Clinical + USS Axilla + CT CAP + Bone scan / PET if indicated</div>
<span class="flow-arrow">↓</span>
<div class="flow-row">
<div class="flow-step green">Stage I–IIA (Operable)</div>
<span class="flow-connector">|</span>
<div class="flow-step orange">Stage IIIA/B (Locally Advanced)</div>
<span class="flow-connector">|</span>
<div class="flow-step">Stage IV (Metastatic)</div>
</div>
<span class="flow-arrow">↓ ↓ ↓</span>
<div class="flow-row">
<div class="flow-step green">BCS + SLNB<br>OR<br>MRM + ALND</div>
<div class="flow-step orange">Neoadjuvant chemo → Surgery → Adj RT</div>
<div class="flow-step purple">Systemic Therapy ± Palliation</div>
</div>
<span class="flow-arrow">↓</span>
<div class="flow-step blue">Adjuvant: Chemo / RT / Hormone / Anti-HER2 based on biology</div>
</div>
<div class="source">Source: Schwartz's 11e, pp.582–598 | Bailey & Love 28e, pp.955–960</div>
</div>
</div>
<!-- ======================== PHYLLODES ======================== -->
<div class="section special" id="phyllodes">
<div class="section-header">
<span class="icon">🌿</span>
<span>PHYLLODES TUMOUR (Cystosarcoma Phyllodes)</span>
<span class="pyq-tag">PYQ</span>
</div>
<div class="section-body">
<div class="card yellow">
<h4>📋 Overview <span class="pyq-tag">PYQ</span></h4>
<ul class="styled">
<li>Named for leaf-like gross cut appearance (<em>phyllodes</em> = leaf-like)</li>
<li><strong>Fibroepithelial tumour</strong> — both stromal and epithelial components</li>
<li>Stromal cells always <strong>monoclonal</strong> (vs fibroadenoma: polyclonal or monoclonal)</li>
<li>Classification: <strong>Benign, Borderline, Malignant</strong></li>
<li>Age: Older than fibroadenoma (mean 45 years)</li>
<li>Grows rapidly; large at presentation</li>
</ul>
</div>
<div class="compare-grid">
<div class="compare-box left">
<h5>Fibroadenoma vs Phyllodes Tumour</h5>
<table>
<thead><tr><th>Feature</th><th>FA</th><th>Phyllodes</th></tr></thead>
<tbody>
<tr><td>Age</td><td><30 yr</td><td>40–50 yr</td></tr>
<tr><td>Size</td><td><4 cm</td><td>Often >5 cm</td></tr>
<tr><td>Growth</td><td>Slow</td><td>Rapid</td></tr>
<tr><td>Stroma cellularity</td><td>Low</td><td>High ↑</td></tr>
<tr><td>Mitoses</td><td>Rare</td><td>Present</td></tr>
<tr><td>Treatment</td><td>Excision / Obs</td><td>Wide excision</td></tr>
</tbody>
</table>
</div>
<div class="compare-box right">
<h5>Treatment</h5>
<ul class="styled">
<li><strong>Wide local excision</strong> with 1–2 cm clear margin (benign & borderline)</li>
<li><strong>Mastectomy</strong> if margins not achievable</li>
<li>Axillary dissection NOT routine (rarely metastasises to nodes)</li>
<li>Malignant phyllodes → haematogenous spread (lungs, bone)</li>
<li>NOT lymph node metastasis as primary route</li>
<li>Recurrence rate: Benign 10–20%, Malignant 25–30%</li>
</ul>
</div>
</div>
<div class="highlight-box danger">
<span class="icon">⚠️</span>
<span><strong>Malignant Phyllodes</strong> contains liposarcomatous or rhabdomyosarcomatous elements. Spreads haematogenously (NOT lymphatics). Axillary dissection is NOT standard. <span class="pyq-tag">PYQ</span></span>
</div>
<div class="source">Source: Schwartz's 11e, pp.600–601 | Sabiston</div>
</div>
</div>
<!-- ======================== SPECIAL TOPICS ======================== -->
<div class="section special" id="special">
<div class="section-header">
<span class="icon">⭐</span>
<span>SPECIAL TOPICS — HIGH YIELD</span>
<span class="pyq-tag">NEET PG</span>
</div>
<div class="section-body">
<h2>Triple Assessment</h2>
<div class="mnemonic">
<div class="label">Mnemonic</div>
<span class="phrase">CEI</span>
<ul>
<li><strong>C</strong>linical Examination (history + physical)</li>
<li><strong>E</strong>valuation with Imaging (Mammography + USS)</li>
<li><strong>I</strong>nvasive Biopsy (Core needle biopsy / FNA)</li>
</ul>
<div style="margin-top:8px;font-size:0.88em;">All 3 must concur before diagnosis. Discordant results → proceed to excision biopsy.</div>
</div>
<h2>Imaging in Breast Disease</h2>
<table>
<thead><tr><th>Modality</th><th>Best For</th><th>Notes</th></tr></thead>
<tbody>
<tr><td><strong>Mammography</strong></td><td>Screening; microcalcifications; >35 yrs</td><td>Sensitivity 85–90%; specificity 90–95%</td></tr>
<tr><td><strong>Ultrasonography</strong></td><td><35 yrs; dense breasts; cyst vs solid; guided biopsy</td><td>First-line in young women</td></tr>
<tr><td><strong>MRI Breast</strong></td><td>BRCA carriers; implant rupture; extent of tumour; occult primary</td><td>Highest sensitivity (90–95%)</td></tr>
<tr><td><strong>PET scan</strong></td><td>Distant metastasis; recurrence; inflammatory Ca</td><td>Not routine; staging advanced disease</td></tr>
<tr><td><strong>FNAC</strong></td><td>LN assessment; cyst drainage; quick diagnosis</td><td>High false negative; not preferred over core biopsy</td></tr>
<tr><td><strong>Core Needle Biopsy</strong></td><td>Histology + ER/PR/HER2 status</td><td>Gold standard for tissue diagnosis</td></tr>
</tbody>
</table>
<div class="card green">
<h4>BI-RADS Classification (ACR)</h4>
<table>
<thead><tr><th>BI-RADS</th><th>Interpretation</th><th>Action</th></tr></thead>
<tbody>
<tr><td><strong>0</strong></td><td>Incomplete</td><td>Additional imaging needed</td></tr>
<tr><td><strong>1</strong></td><td>Negative</td><td>Routine screening</td></tr>
<tr><td><strong>2</strong></td><td>Benign</td><td>Routine screening</td></tr>
<tr><td><strong>3</strong></td><td>Probably benign (<2% malignancy)</td><td>6-month follow-up USS</td></tr>
<tr><td><strong>4</strong></td><td>Suspicious (2–95%)</td><td>Biopsy recommended</td></tr>
<tr><td><strong>5</strong></td><td>Highly suspicious (>95%)</td><td>Biopsy mandatory</td></tr>
<tr><td><strong>6</strong></td><td>Biopsy-proven malignancy</td><td>Treatment</td></tr>
</tbody>
</table>
</div>
<h2>Male Breast Cancer</h2>
<div class="card green">
<h4>Key Points <span class="pyq-tag">PYQ</span></h4>
<ul class="styled">
<li><1% of all breast cancers; 1.5% of all male cancers in US</li>
<li>Peak incidence: <strong>6th decade</strong></li>
<li>Preceded by gynaecomastia in <strong>20%</strong></li>
<li>Associations: <strong>Klinefelter's syndrome (XXY)</strong>, oestrogen therapy, testicular feminisation, BRCA2</li>
<li>>85% = Infiltrating ductal carcinoma; <strong>~80% are ER+</strong></li>
<li>Treatment: <strong>Modified Radical Mastectomy (MRM)</strong> is standard</li>
<li>Adjuvant tamoxifen for ER+ tumours</li>
<li>Same stage-for-stage survival as female breast cancer; overall worse prognosis due to later presentation</li>
</ul>
</div>
<h2>Breast Cancer in Pregnancy</h2>
<div class="card green">
<ul class="styled">
<li>MRI (without gadolinium) preferred over mammography</li>
<li><strong>Surgery safe in all trimesters</strong></li>
<li><strong>Chemotherapy safe in 2nd & 3rd trimester</strong> (avoid 1st trimester — teratogenicity)</li>
<li><strong>Radiotherapy CONTRAINDICATED</strong> in pregnancy → delay till after delivery or perform MRM</li>
<li><strong>Tamoxifen CONTRAINDICATED</strong> in pregnancy</li>
<li>Pregnancy does NOT worsen prognosis if stage-matched</li>
</ul>
</div>
<h2>Peau d'Orange</h2>
<div class="card green">
<ul class="styled">
<li>"Orange peel" skin appearance</li>
<li>Due to: <strong>Dermal lymphatic invasion</strong> → lymphoedema of skin → dimpling at hair follicles</li>
<li>Seen in: Inflammatory breast Ca, Locally Advanced Breast Ca</li>
<li>NOT the same as skin dimpling from Cooper's ligament shortening (which is focal)</li>
</ul>
</div>
<h2>Lymphoedema Post-Axillary Dissection</h2>
<div class="card green">
<ul class="styled">
<li>Most important complication of axillary lymph node dissection</li>
<li>Risk reduced significantly with SLNB</li>
<li>Treatment: Physiotherapy, compression garments, microsurgical lymphovenous bypass</li>
<li>Stewart-Treves syndrome: <strong>Lymphangiosarcoma</strong> arising in chronic post-mastectomy lymphoedematous arm</li>
</ul>
</div>
<div class="source">Source: Schwartz's 11e, pp.590–602 | Bailey & Love 28e</div>
</div>
</div>
<!-- ======================== PYQs ======================== -->
<div class="section pyq" id="pyqs">
<div class="section-header">
<span class="icon">❓</span>
<span>PREVIOUS YEAR QUESTIONS (PYQs) — NEET PG / INICET PATTERN</span>
</div>
<div class="section-body">
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern | Surgery | High Yield</span>
<span>Anatomy</span>
</div>
<div class="pyq-q">Q1. The most common site of breast carcinoma is:</div>
<div class="pyq-options">
<div>A. Upper inner quadrant</div>
<div>B. Lower outer quadrant</div>
<div class="correct-option">C. Upper outer quadrant ✓</div>
<div>D. Subareolar region</div>
</div>
<div class="pyq-answer">✅ Answer: C — Upper outer quadrant (60% of breast cancers). Contains the most breast tissue and the axillary tail.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern | Surgery</span>
<span>Nipple Discharge</span>
</div>
<div class="pyq-q">Q2. Most common cause of bloodstained nipple discharge in a 35-year-old woman:</div>
<div class="pyq-options">
<div>A. Intraductal carcinoma</div>
<div class="correct-option">B. Intraductal papilloma ✓</div>
<div>C. Duct ectasia</div>
<div>D. Phyllodes tumour</div>
</div>
<div class="pyq-answer">✅ Answer: B — Intraductal papilloma is the MC cause (~75%). Carcinoma causes bloody discharge in older women. Remember: "Blood from one duct in a young woman = Papilloma until proven otherwise."</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG / INICET Pattern</span>
<span>Staging</span>
</div>
<div class="pyq-q">Q3. A 45-yr woman has breast cancer with ipsilateral supraclavicular lymph node involvement and no distant metastasis. As per AJCC 8th edition, this is:</div>
<div class="pyq-options">
<div>A. Stage IV</div>
<div>B. Stage IIIA</div>
<div class="correct-option">C. Stage III (N3) ✓</div>
<div>D. Stage IIB</div>
</div>
<div class="pyq-answer">✅ Answer: C — Supraclavicular node involvement = N3 = Stage III (NOT Stage IV). This changed in AJCC 6th edition onwards. Classic PYQ!</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern</span>
<span>Treatment</span>
</div>
<div class="pyq-q">Q4. Radical mastectomy (Halsted) differs from Modified Radical Mastectomy in:</div>
<div class="pyq-options">
<div class="correct-option">A. Pectoralis major muscle is also removed in Halsted ✓</div>
<div>B. Axillary dissection is more extensive in MRM</div>
<div>C. MRM removes pectoralis minor</div>
<div>D. MRM includes internal mammary nodes</div>
</div>
<div class="pyq-answer">✅ Answer: A — Halsted's radical mastectomy removes breast + pec major + pec minor + ALL axillary nodes. MRM (Patey/Auchincloss) preserves pectoralis major. MRM is now the standard operation.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>INICET Pattern</span>
<span>Benign Disease</span>
</div>
<div class="pyq-q">Q5. In ANDI classification, fibroadenoma is an aberration of which phase?</div>
<div class="pyq-options">
<div class="correct-option">A. Lobular development (15–25 years) ✓</div>
<div>B. Cyclical change (15–50 years)</div>
<div>C. Involution (35–55 years)</div>
<div>D. Ductal involution</div>
</div>
<div class="pyq-answer">✅ Answer: A — Fibroadenoma is an aberration of the development phase (15–25 yrs). Cysts = involution phase. Cyclical mastalgia = cyclical change phase.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern</span>
<span>Special Topics</span>
</div>
<div class="pyq-q">Q6. Paget's disease of the nipple is characterised by:</div>
<div class="pyq-options">
<div>A. Absence of underlying carcinoma</div>
<div class="correct-option">B. Large, pale, vacuolated Paget cells in the epithelium ✓</div>
<div>C. S-100 positive cells</div>
<div>D. Haematogenous spread to axilla</div>
</div>
<div class="pyq-answer">✅ Answer: B — Paget cells (large, pale, vacuolated) in rete pegs = pathognomonic. CEA positive (not S-100, which is for melanoma). Almost always associated with underlying DCIS or invasive Ca.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern</span>
<span>Phyllodes</span>
</div>
<div class="pyq-q">Q7. In malignant phyllodes tumour, the most common mode of spread is:</div>
<div class="pyq-options">
<div>A. Lymphatic spread to axillary nodes</div>
<div class="correct-option">B. Haematogenous spread to lungs ✓</div>
<div>C. Direct spread to chest wall</div>
<div>D. Peritoneal seeding</div>
</div>
<div class="pyq-answer">✅ Answer: B — Malignant phyllodes spreads haematogenously (lung, bone) NOT via lymphatics. Hence axillary dissection is NOT routinely done. This differentiates it from carcinoma.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>INICET Pattern</span>
<span>Treatment</span>
</div>
<div class="pyq-q">Q8. Sentinel lymph node biopsy uses which combination of agents?</div>
<div class="pyq-options">
<div>A. Indigo carmine + radioactive iodine</div>
<div class="correct-option">B. Patent blue dye + Tc-99m nanocolloid ✓</div>
<div>C. Methylene blue + ICG fluorescence</div>
<div>D. Patent blue + radioactive iodine</div>
</div>
<div class="pyq-answer">✅ Answer: B — Sentinel LN biopsy uses Patent Blue V (isosulfan blue) + Technetium-99m labelled nanocolloid. Combined technique gives >95% identification rate. ICG (indocyanine green) is also now used in some centres.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG Pattern</span>
<span>Breast Cancer Biology</span>
</div>
<div class="pyq-q">Q9. Triple Negative Breast Cancer (ER−/PR−/HER2−) is associated with mutation in:</div>
<div class="pyq-options">
<div class="correct-option">A. BRCA1 ✓</div>
<div>B. BRCA2</div>
<div>C. TP53 only</div>
<div>D. PTEN</div>
</div>
<div class="pyq-answer">✅ Answer: A — BRCA1 mutations are associated with Triple-Negative Breast Cancer (basal-like subtype). BRCA2 is associated with ER+ luminal cancers and male breast cancer. TNBC is treated with chemotherapy only.</div>
</div>
<div class="pyq-card">
<div class="pyq-header">
<span>NEET PG / INICET Pattern</span>
<span>Inflammatory Breast Ca</span>
</div>
<div class="pyq-q">Q10. Which of the following is TRUE about Inflammatory Breast Carcinoma?</div>
<div class="pyq-options">
<div>A. Immediate reconstruction is recommended</div>
<div>B. Surgery is the primary treatment</div>
<div class="correct-option">C. Neoadjuvant chemotherapy is given first ✓</div>
<div>D. BCS is the treatment of choice</div>
</div>
<div class="pyq-answer">✅ Answer: C — Inflammatory breast Ca: Neoadjuvant chemotherapy → Modified Radical Mastectomy (no BCS, no skin/nipple sparing) → Radiation therapy. Immediate reconstruction is CONTRAINDICATED. Poorest prognosis among all breast cancers.</div>
</div>
</div>
</div>
<!-- ======================== ALL MNEMONICS ======================== -->
<div class="section special" id="mnemonics">
<div class="section-header">
<span class="icon">🧠</span>
<span>ALL MNEMONICS — RAPID RECALL</span>
</div>
<div class="section-body">
<div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;">
<div class="mnemonic">
<div class="label">Fibroadenoma Features</div>
<span class="phrase">SNURL</span>
<ul>
<li><strong>S</strong>mooth, mobile ("Breast Mouse")</li>
<li><strong>N</strong>on-tender</li>
<li><strong>U</strong>pper outer quadrant (MC)</li>
<li><strong>R</strong>ubber consistency</li>
<li><strong>L</strong>obulated surface</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Contraindications to BCS</div>
<span class="phrase">MMARSPS</span>
<ul>
<li><strong>M</strong>ulticentric tumour</li>
<li><strong>M</strong>icrocalcifications (diffuse)</li>
<li><strong>A</strong>nkylosing spondylitis</li>
<li><strong>R</strong>adiation (prior chest RT)</li>
<li><strong>S</strong>LE / collagen vascular disease</li>
<li><strong>P</strong>ositive margins ×2 re-excisions</li>
<li><strong>S</strong>evere orthopnoea</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Risk Factors for Breast Cancer</div>
<span class="phrase">FEMALES</span>
<ul>
<li><strong>F</strong>amily history / BRCA gene</li>
<li><strong>E</strong>arly menarche / Late menopause</li>
<li><strong>M</strong>ultiparity = protective (nulliparity = risk)</li>
<li><strong>A</strong>ge (post-menopausal obesity)</li>
<li><strong>L</strong>ate first pregnancy (>35 yr)</li>
<li><strong>E</strong>xogenous oestrogen (HRT, OCP)</li>
<li><strong>S</strong>moking / Alcohol / Radiation</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Types of Mastectomy (Historical)</div>
<span class="phrase">SIMPLE → MRM → RADICAL → EXTENDED</span>
<ul>
<li><strong>S</strong>imple = Breast only</li>
<li><strong>MRM</strong> (Patey) = Breast + Pec minor + Axilla</li>
<li><strong>MRM</strong> (Auchincloss) = Breast + Axilla only</li>
<li><strong>R</strong>adical (Halsted) = + Pec major</li>
<li><strong>E</strong>xtended (Urban) = + Internal mammary nodes</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Prognosis Best → Worst Special Types</div>
<span class="phrase">TMPMI</span>
<ul>
<li><strong>T</strong>ubular = Best</li>
<li><strong>M</strong>ucinous / Colloid = Excellent</li>
<li><strong>P</strong>apillary = Good</li>
<li><strong>M</strong>edullary = Better than NST</li>
<li><strong>I</strong>nfiltrating ductal NST = Worst common</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Causes of Nipple Retraction</div>
<span class="phrase">DAMP</span>
<ul>
<li><strong>D</strong>uct ectasia (bilateral, slit-like)</li>
<li><strong>A</strong>denocarcinoma (acquired, unilateral)</li>
<li><strong>M</strong>astitis / periductal (with fistula)</li>
<li><strong>P</strong>hysiological / Congenital (inverted nipple)</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">Bony Metastasis in Breast Cancer</div>
<span class="phrase">LFTRS (Frequency Order)</span>
<ul>
<li><strong>L</strong>umbar vertebrae (MC)</li>
<li><strong>F</strong>emoral neck</li>
<li><strong>T</strong>horacic vertebrae</li>
<li><strong>R</strong>ibs</li>
<li><strong>S</strong>kull</li>
</ul>
</div>
<div class="mnemonic">
<div class="label">T staging sizes</div>
<span class="phrase">0 – 2 – 5 – ∞</span>
<ul>
<li>T1 = ≤ 2 cm</li>
<li>T2 = 2–5 cm</li>
<li>T3 = >5 cm</li>
<li>T4 = Any size + skin/chest wall</li>
</ul>
</div>
</div>
<!-- Quick Reference Box -->
<div class="recall-box" style="margin-top:24px;">
<div class="label">⚡ RAPID RECALL — Professor's Key Points</div>
<p>
🏆 <strong>MC breast cancer site:</strong> UOQ (60%) |
🏆 <strong>MC benign breast tumour <30 yr:</strong> Fibroadenoma |
🏆 <strong>MC cause of bloody discharge:</strong> Intraductal papilloma | <br>
🏆 <strong>Worst prognosis:</strong> Inflammatory breast Ca |
🏆 <strong>Best prognosis special type:</strong> Tubular/Mucinous |
🏆 <strong>Standard operation:</strong> MRM (not Halsted) | <br>
🏆 <strong>LCIS:</strong> Bilateral risk marker (NOT a precursor) |
🏆 <strong>DCIS:</strong> Local precursor (NOT bilateral) |
🏆 <strong>Supraclavicular node:</strong> N3, Stage III (NOT Stage IV) | <br>
🏆 <strong>Phyllodes spread:</strong> Haematogenous (NOT lymphatics) |
🏆 <strong>Inflammatory Ca Tx:</strong> Neoadjuvant chemo FIRST |
🏆 <strong>BRCA1 → Triple Negative; BRCA2 → Luminal/Male breast Ca</strong>
</p>
</div>
</div>
</div>
<!-- ======================== FOOTER ======================== -->
<div style="text-align:center;padding:30px;color:#9e9e9e;font-size:0.82em;margin-top:20px;">
<div style="font-size:1.5em;margin-bottom:10px;">🎀</div>
<p><strong>Sources:</strong> Bailey & Love's Short Practice of Surgery 28th Ed. • Schwartz's Principles of Surgery 11th Ed. • Sabiston Textbook of Surgery</p>
<p style="margin-top:6px;">Prepared for NEET PG / INICET 2025–26 • All rights of source textbooks belong to their respective publishers</p>
<p style="margin-top:6px;color:#e91e63;font-weight:600;">Best of Luck! 🌟 You've got this!</p>
</div>
</body>
</html>
Running Command
wc -l /home/daytona/workspace/breast-surgery-notes/breast_surgery_neetpg.html && ls -lh /home/daytona/workspace/breast-surgery-notes/
Your NEET PG / INICET Breast Surgery Rapid Revision Notes are ready! 🎀
📥 Download Your Notes
breast surgery neetpg
HTML File · HTML
81 KB | Open in any browser | Print-ready | Mobile responsive
📋 What's Inside (1752-line aesthetic document)
| Section | Content |
|---|---|
| 🔬 Surgical Anatomy | Blood supply, lymphatics (Level I/II/III), Cooper's ligaments, TDLU, Quadrants diagram (SVG) |
| 🌱 ANDI Concept | Full table — Development/Cyclical/Involution phases with cancer risk (RR) table |
| 🟢 Benign Disease | Fibroadenoma, Breast cysts, Galactocele, Mastalgia — management flowcharts |
| 💧 Nipple Discharge | Complete diagnostic chart, Microdochectomy vs Hadfield's procedure |
| 🔴 Breast Abscess | Lactational vs Non-lactational, Mammary duct fistula (Zuska's), Granulomatous mastitis |
| ⚠️ Breast Carcinoma | Epidemiology, Risk factors, BRCA1/2, Foote & Stewart classification table |
| 🔬 Histopathology | All 8 types with %, molecular subtypes (Luminal A/B, HER2, Triple-negative), DCIS vs LCIS |
| 📊 TNM Staging | Full AJCC 8th Ed tables (T, N, M), 5-year survival by stage |
| 💊 Treatment | All mastectomy types (Halsted vs Patey vs Auchincloss), BCS indications/contraindications, SLNB, complete adjuvant therapy table |
| 🌿 Phyllodes | FA vs Phyllodes comparison, spread patterns |
| ❓ 10 PYQs | NEET PG & INICET pattern questions with detailed answers |
| 🧠 8 Mnemonics | SNURL, FEMALES, DICED, SLAP, TMPMI, DAMP, CEI, LFTRS |
| ⚡ Quick Recall | Professor's 12 key exam-clincher points |
How to use
- Open in Chrome/Firefox - fully renders with colour coding, diagrams and flowcharts
- Ctrl+P to print as PDF for offline study
- Use the coloured navigation pills at the top to jump between sections
Sources: Bailey & Love 28e · Schwartz's Principles of Surgery 11e · Sabiston Textbook
This is a shared conversation. Sign in to Orris to start your own chat.